Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Low Medicare Part D Enrollment Could Cause Sponsors To “Retrench” – Attorney

This article was originally published in The Pink Sheet Daily

Executive Summary

Slow enrollment could result in “significant consolidation” within 18 to 24 months, Sonnenschein Nath & Rosenthal partner Fried says during Drug & Device Dialogue audio conference. He also suggests that the large number of applicants seeking to sponsor Part D plans resulted from a defensive business stance by potential sponsors.

You may also be interested in...



Medicare Rx Plan Numbers Will Not Match Card Sponsor Totals, CMS’ McClellan Predicts

Seniors will not be overwhelmed by a high number of plan choices, the agency administrator maintains. CMS has received a large volume of Part D applications, but not all look “complete and serious,” McClellan indicates.

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.

User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles

A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel